<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016861</url>
  </required_header>
  <id_info>
    <org_study_id>TCCC-H-6957</org_study_id>
    <secondary_id>CDR0000068568</secondary_id>
    <secondary_id>TCCC-GCRC-0654</secondary_id>
    <secondary_id>NCI-V01-1654</secondary_id>
    <nct_id>NCT00016861</nct_id>
  </id_info>
  <brief_title>Irinotecan in Treating Children With Refractory or Progressive Solid Tumors</brief_title>
  <official_title>Pediatric Phase I and Pharmacokinetic Study of Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Children's Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have&#xD;
      refractory or progressive solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan in&#xD;
           children with refractory or progressive solid tumors.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug and its metabolites (SN-38, SN-38G, and APC)&#xD;
           administered with and without concurrent anticonvulsants in this patient population.&#xD;
&#xD;
        -  Determine the benefit this drug offers this patient population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are accrued into stratum 1&#xD;
      initially and into stratum 2 if stratum 1 closes due to dose-limiting toxicity of&#xD;
      myelosuppression or diarrhea. Patients on anticonvulsants will be accrued into stratum 3 and&#xD;
      must meet the eligibility criteria for the stratum that is open (stratum 1 or stratum 2).&#xD;
      (Stratum 1 closed as of 2002-09-15).&#xD;
&#xD;
      Patients receive irinotecan IV over 90 minutes weekly for 4 weeks. Treatment repeats every 6&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated&#xD;
      dose (MTD) with and without anticonvulsants is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 6 months for 4 years and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor refractory to standard therapy&#xD;
             or for which no known effective therapy exists&#xD;
&#xD;
               -  Brain tumors eligible&#xD;
&#xD;
                    -  Histologic verification waived for brain stem gliomas&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
          -  No bone marrow involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  1 to 21&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100% (over age 10)&#xD;
&#xD;
          -  Lansky 50-100% (age 10 and under)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT less than 5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 6 months since prior autologous bone marrow transplantation (BMT) (not&#xD;
             including stem cell rescue after high-dose chemotherapy)&#xD;
&#xD;
          -  At least 1 week since prior growth factors&#xD;
&#xD;
          -  No prior BMT with total body irradiation (stratum I)&#xD;
&#xD;
          -  No prior BMT with or without total body irradiation (stratum 2)&#xD;
&#xD;
          -  No prior allogeneic BMT (all strata)&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  No other concurrent prophylactic growth factor support during the first course of&#xD;
             therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  No more than 2 prior multi-agent chemotherapy regimens (stratum 2)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent dexamethasone allowed if on stable or decreasing dose for at least 2 weeks&#xD;
             prior to study&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or more&#xD;
             of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  No prior central axis radiotherapy, pelvic radiotherapy, and/or total abdominal&#xD;
             radiotherapy (stratum 2)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital,&#xD;
             carbamazepine) allowed if on stable dose for at least 2 weeks prior to study (stratum&#xD;
             3)&#xD;
&#xD;
          -  Concurrent valproic acid allowed if combined with another enzyme inducing&#xD;
             anticonvulsant drug (stratum 3)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. Blaney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

